Skip to Content
Merck

MAB8257B

Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated

clone A1, Chemicon®, from mouse

Sign In to View Organizational & Contract Pricing

Select a Size

100 μG

€533.00

€533.00


Check Cart for Availability

Request a Bulk Order

About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

mouse

Quality Level

conjugate

biotin conjugate

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

A1, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

immunofluorescence: suitable

isotype

IgG2a

shipped in

wet ice

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
MAB8257MAB8257FMAB8251
biological source

mouse

biological source

mouse

biological source

mouse

biological source

mouse

antibody form

purified immunoglobulin

antibody form

purified immunoglobulin

antibody form

purified antibody

antibody form

ascites fluid

clone

A1, monoclonal

clone

A1, monoclonal

clone

A1, monoclonal

clone

A1, monoclonal, A3, monoclonal

species reactivity

human

species reactivity

human

species reactivity

human

species reactivity

human

conjugate

biotin conjugate

conjugate

-

conjugate

FITC conjugate

conjugate

-

technique(s)

immunofluorescence: suitable

technique(s)

immunofluorescence: suitable

technique(s)

immunofluorescence: suitable

technique(s)

immunofluorescence: suitable

Immunogen

Epitope: nucleoprotein
Influenza A

Application

Detect Influenza A using this Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated validated for use in IF.
Immunofluorescence

Optimal dilutions must be determined by end user.
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral

Biochem/physiol Actions

Specific for the Influenza A nucleoprotein. Has stronger binding with N1-type Flu A. Has been shown to react with the H5N1 strain. No cross reactivity seen to influenza B or other respiratory viruses.

Physical form

Biotin conjugated purified immunoglobulin. Liquid in 0.01M PBS, pH=7.1, 0.1% Sodium Azide with 15 mg/mL BSA as stabilizer.

Preparation Note

Maintain at 2 to 8°C for up to 12 months from date of receipt. Protect from Light.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Erin E H Tran et al.
mBio, 7(2), e00257-e00257 (2016-03-24)
Influenza viruses expressing chimeric hemagglutinins (HAs) are important tools in the quest for a universal vaccine. Using cryo-electron tomography, we have determined the structures of a chimeric HA variant that comprises an H1 stalk and an H5 globular head domain
Sergey Yegorov et al.
Cell reports. Medicine, 3(2), 100509-100509 (2022-03-05)
The induction of broadly neutralizing antibodies (bNAbs) that target the hemagglutinin stalk domain is a promising strategy for the development of "universal" influenza virus vaccines. bNAbs can be boosted in adults by sequential exposure to heterosubtypic viruses through natural infection
Felix Broecker et al.
NPJ vaccines, 4, 31-31 (2019-07-26)
Current seasonal influenza virus vaccines only provide limited, short-lived protection, and antigenic drift in the hemagglutinin surface glycoprotein necessitates their annual re-formulation and re-administration. To overcome these limitations, universal vaccine strategies that aim at eliciting broadly protective antibodies to conserved
Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection.
Koutsonanos, DG; Vassilieva, EV; Stavropoulou, A; Zarnitsyn, VG; Esser, ES; Taherbhai et al.
Scientific Reports null
Kai Wu et al.
ACS applied materials & interfaces, 14(8), 9945-9969 (2022-02-16)
The giant magnetoresistance (GMR) effect has seen flourishing development from theory to application in the last three decades since its discovery in 1988. Nowadays, commercial devices based on the GMR effect, such as hard-disk drives, biosensors, magnetic field sensors, microelectromechanical

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service